Thane Wettig - FibroGen Ex Officer
| FGEN Stock | MXN 7.16 0.34 4.53% |
Insider
Thane Wettig is Ex Officer of FibroGen
| Age | 58 |
| Phone | 415 978 1200 |
| Web | https://www.fibrogen.com |
Thane Wettig Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thane Wettig against FibroGen stock is an integral part of due diligence when investing in FibroGen. Thane Wettig insider activity provides valuable insight into whether FibroGen is net buyers or sellers over its current business cycle. Note, FibroGen insiders must abide by specific rules, including filing SEC forms every time they buy or sell FibroGen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thane Wettig over two months ago Acquisition by Thane Wettig of 1300000 shares of FibroGen at 0.6508 subject to Rule 16b-3 | ||
Thane Wettig over six months ago Disposition of 20840 shares by Thane Wettig of FibroGen at 0.47 subject to Rule 16b-3 | ||
Thane Wettig over six months ago Disposition of 472 shares by Thane Wettig of FibroGen at 17.0356 subject to Rule 16b-3 | ||
Thane Wettig over six months ago Disposition of 782 shares by Thane Wettig of FibroGen at 1.13 subject to Rule 16b-3 |
FibroGen Management Efficiency
The company has return on total asset (ROA) of (0.2656) % which means that it has lost $0.2656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8478) %, meaning that it generated substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kyehyun Kyung | Samsung Electronics Co | 60 | |
| Benjamin Polk | Monster Beverage Corp | 68 | |
| TaeMoon Roh | Samsung Electronics Co | 55 | |
| Mark Vidergauz | Monster Beverage Corp | 65 | |
| Catherine Cheetham | Lloyds Banking Group | 60 | |
| John Chambers | Lloyds Banking Group | N/A | |
| JungBae Lee | Samsung Electronics Co | 56 | |
| Steven Pizula | Monster Beverage Corp | 63 | |
| JongHee Han | Samsung Electronics Co | 61 | |
| Emelie Tirre | Monster Beverage Corp | 53 | |
| James Dinkins | Monster Beverage Corp | 56 | |
| Charles Nunn | Lloyds Banking Group | 52 | |
| Tilak Mandadi | CVS Health | 59 | |
| David Gledhill | Lloyds Banking Group | 61 | |
| Laurie Havanec | CVS Health | 62 | |
| Hark Park | Samsung Electronics Co | 59 | |
| Jaeseung Lee | Samsung Electronics Co | 63 | |
| Alan MD | CVS Health | 61 | |
| William Chalmers | Lloyds Banking Group | 55 | |
| Guy Carling | Monster Beverage Corp | 46 | |
| Letitia Smith | Lloyds Banking Group | 57 | |
Management Performance
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 |
FibroGen Leadership Team
Elected by the shareholders, the FibroGen's board of directors comprises two types of representatives: FibroGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroGen. The board's role is to monitor FibroGen's management team and ensure that shareholders' interests are well served. FibroGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mr JD, Chief Officer | ||
| Enrique Conterno, CEO Director | ||
| Barry Berkowitz, Founder | ||
| Christine Chung, VP Operations | ||
| Elias Kouchakji, Drug Devel | ||
| Juan Graham, Chief Officer | ||
| Karen Bergman, VP Communications | ||
| Thane Wettig, Ex Officer | ||
| MPH MD, Ex Officer | ||
| John Hunter, Chief Officer |
FibroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (2.94) % | |||
| Operating Margin | (2.52) % | |||
| Current Valuation | 21.87 B | |||
| Shares Outstanding | 93.96 M | |||
| Shares Owned By Insiders | 7.82 % | |||
| Shares Owned By Institutions | 78.80 % | |||
| Price To Book | 54.45 X | |||
| Price To Sales | 231.63 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.